8-Hydroxy-11,12-epoxyeicosa-5,9,14-trienoic acid | 85589-24-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 8-Hydroxy-11,12-epoxyeicosa-5,9,14-trienoic acid
• 英文别名: (5E,9E)-8-hydroxy-10-[3-[(E)-oct-2-enyl]oxiran-2-yl]deca-5,9-dienoic acid
• CAS: 85589-24-8；94161-11-2
• 化学式: C₂₀H₃₂O₄
• 分子量: 336.5
• InChiKey: SGTUOBURCVMACZ-LMIMMGIZSA-N

物化性质

• 沸点：
  483.3±45.0 °C(Predicted)
• 密度：
  1.078±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  24
• 可旋转键数：
  14
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  70.1
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Agents with leukotriene B4-like antiviral (DNA) and anti-neoplastic activities
  申请人：——

  公开号：US20040132820A1

  公开（公告）日：2004-07-08

  The present invention relates to the use of the antiviral activity of exogenous leukotriene B 4 (LTB 4 ), variants and derivatives thereof as a therapeutic agent in viral infections caused by human and animal viruses. The present invention also relates to the use of LTB 4 as an anti-neoplastic agent in the prophylaxis and treatment of cancers induced by tumor viruses and in other neoplasic diseases. The human and animal viruses are DNA viruses, such as parvoviridae, papovaviridae, adenoviridae, herpesviridae, poxyviridae and hepadnaviridae; RNA viruses, such as picornaviridae, togaviridae, orthomyxoviridae, paramyxoviridae, coronaviridae, reoviridae, and filoviridae in general, and Retroviridae such as HIV-1 and HIV-2.

  本发明涉及利用外源性白三烯 B 4 (LTB 4 )、其变体和衍生物的抗病毒活性作为人类和动物病毒引起的病毒感染的治疗剂。本发明还涉及使用 LTB 4 作为抗肿瘤剂，用于预防和治疗由肿瘤病毒诱发的癌症和其他肿瘤性疾病。人类和动物病毒包括 DNA 病毒，如副病毒科、乳头瘤病毒科、腺病毒科、疱疹病毒科、poxyviridae 和 hepadnaviridae；RNA 病毒，如 picornaviridae、togaviridae、orthomyxoviridae、paramyxoviridae、coronaviridae、reoviridae 和 filoviridae，以及逆转录病毒科，如 HIV-1 和 HIV-2。
• In vivo release of endogenous anti-microbial mediators by leukotriene B4 (LTB4) administration
  申请人：Gosselin Jean

  公开号：US20050239889A1

  公开（公告）日：2005-10-27

  The invention relates to the in vivo release of endogenous anti-microbial mediators using leukotriene B4 administration. The present invention furthermore relates to the use of leukotriene B4 for the treatment and/or prophylaxis of diseases that are positively influenced by such anti-microbial mediators.

  本发明涉及使用白三烯 B4 在体内释放内源性抗微生物介质。本发明还涉及使用白三烯 B4 治疗和/或预防受此类抗微生物介质积极影响的疾病。
• Ltb4 as vaccine adjuvant
  申请人：——

  公开号：US20040208882A1

  公开（公告）日：2004-10-21

  The present invention relates to a vaccine adjuvant for enhancing immune response of an individual to a vaccine, which comprises an immune-enhancing effective amount of an LTB4 agent in association with a pharmaceutically effective vaccine carrier.
• Agents with leukotriene B4-like antiviral (enveloped RNA) activities
  申请人：Gosselin Jean

  公开号：US20060025479A1

  公开（公告）日：2006-02-02

  The present invention relates to the use of the antiviral activity of exogenous leukotriene B 4 (LTB 4 ), variants and derivatives thereof as a therapeutic agent in viral infections caused by human and animal enveloped RNA viruses. The human and animal enveloped RNA viruses are RNA viruses, such as togaviridae, orthomyxoviridae, paramyxoviridae, coronaviridae, filoviridae, arenaviridae, bunyaviridae, rhabdoviridae and flaviviridae in general, and Retroviridae such as HIV-1 and HIV-2.
• US5789441A
  申请人：——

  公开号：US5789441A

  公开（公告）日：1998-08-04